Zealand Pharma A/S (OTCMKTS:ZLDPF) Upgraded to "Hold" at Zacks Research

Key Points

• Zacks Research upgraded Zealand Pharma A/S from a "strong sell" to a "hold" rating, indicating a shift in sentiment towards the stock.
• The company has attracted multiple upgrades from prominent firms, including strong-buy ratings from BNP Paribas, Wells Fargo, and Barclays.
• Despite missing earnings expectations, Zealand Pharma maintains a strong market position with a market cap of $4.87 billion and an average rating of "Strong Buy".

Zacks Research upgraded shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) from a strong sell rating to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports.

A number of other research firms also recently issued reports on ZLDPF. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Tuesday, July 1st. Barclays upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. Finally, Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Five analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Strong Buy".

Zealand Pharma A/S Trading Up 6.2%

ZLDPF stock traded up $4.31 on Monday, hitting $73.31. 130 shares of the company were exchanged, compared to its average volume of 156. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.09 and a quick ratio of 15.08. The stock has a market capitalization of $5.21 billion, a price-to-earnings ratio of 5.15 and a beta of 0.73. Zealand Pharma A/S has a twelve month low of $49.98 and a twelve month high of $135.65. The business's fifty day moving average is $60.98 and its two-hundred day moving average is $65.55.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). The company had revenue of $1.43 billion for the quarter, compared to analysts' expectations of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. As a group, research analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.